Scinai Immunotherapeutics
Open
$0.72
Prev. Close
$0.72
High
$0.73
Low
$0.72
Market Snapshot
0.00
$658K
31
Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
emptyResult
Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Recently from Cashu
Scinai Immunotherapeutics Launches Scinai Biopharma Services Following Strategic Reorganization and Acquisition.
Scinai Immunotherapeutics Ltd. has successfully completed a strategic reorganization, paving the way for the launch of Scinai Biopharma Services Ltd., a dedicated Contract Development and Manufacturin…
Scinai Immunotherapeutics Launches CDMO Platform to Boost Efficiency and Revenue Growth.
Scinai Immunotherapeutics Streamlines Operations with New CDMO Platform Scinai Immunotherapeutics Ltd. has recently completed a strategic corporate reorganization that has given birth to a dedicated c…
Scinai Immunotherapeutics Prepares for BIO-Europe Spring 2026 to Enhance Global Biopharma Presence
Scinai Immunotherapeutics: Strengthening Presence in Global Biopharmaceutical Landscape Scinai Immunotherapeutics Ltd., a biopharmaceutical company focused on innovative inflammation and immunology th…
Scinai Immunotherapeutics Navigates Nasdaq Compliance Challenge Amid Stock Price Concerns
Scinai Immunotherapeutics Faces Nasdaq Compliance Challenge Scinai Immunotherapeutics Ltd., a biopharmaceutical firm specializing in innovative immunotherapy solutions, finds itself navigating a compl…